Skip to main content
NASDAQ:NEOG

Neogen Competitors

$91.10
+1.54 (+1.72 %)
(As of 05/13/2021 10:59 AM ET)
Add
Compare
Today's Range
$90.10
$91.36
50-Day Range
$85.11
$96.67
52-Week Range
$62.49
$97.70
Volume535 shs
Average Volume207,734 shs
Market Capitalization$4.87 billion
P/E Ratio79.91
Dividend YieldN/A
Beta0.5

Competitors

Neogen (NASDAQ:NEOG) Vs. ALGN, WST, COO, XRAY, STAA, and QDEL

Should you be buying NEOG stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to Neogen, including Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), STAAR Surgical (STAA), and Quidel (QDEL).

Align Technology (NASDAQ:ALGN) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a summary of current recommendations and price targets for Align Technology and Neogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Align Technology111002.75
Neogen02102.33

Align Technology presently has a consensus target price of $627.0909, suggesting a potential upside of 12.84%. Neogen has a consensus target price of $81.50, suggesting a potential downside of 10.54%. Given Align Technology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Align Technology is more favorable than Neogen.

Earnings and Valuation

This table compares Align Technology and Neogen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$2.41 billion18.29$442.78 million$4.96112.14
Neogen$418.17 million11.66$59.47 million$1.1380.62

Align Technology has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

85.8% of Align Technology shares are held by institutional investors. Comparatively, 92.8% of Neogen shares are held by institutional investors. 1.2% of Align Technology shares are held by company insiders. Comparatively, 0.9% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, Neogen has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

Profitability

This table compares Align Technology and Neogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Align Technology76.00%68.99%46.64%
Neogen13.92%8.13%7.45%

Summary

Align Technology beats Neogen on 12 of the 14 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares West Pharmaceutical Services and Neogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
West Pharmaceutical Services14.69%19.01%12.78%
Neogen13.92%8.13%7.45%

Institutional & Insider Ownership

92.6% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 92.8% of Neogen shares are held by institutional investors. 1.6% of West Pharmaceutical Services shares are held by company insiders. Comparatively, 0.9% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares West Pharmaceutical Services and Neogen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$1.84 billion13.21$241.70 million$3.24101.58
Neogen$418.17 million11.66$59.47 million$1.1380.62

West Pharmaceutical Services has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for West Pharmaceutical Services and Neogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
West Pharmaceutical Services01202.67
Neogen02102.33

West Pharmaceutical Services presently has a consensus target price of $310.00, suggesting a potential downside of 5.81%. Neogen has a consensus target price of $81.50, suggesting a potential downside of 10.54%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, equities research analysts clearly believe West Pharmaceutical Services is more favorable than Neogen.

Risk & Volatility

West Pharmaceutical Services has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Neogen has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

Summary

West Pharmaceutical Services beats Neogen on 13 of the 14 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Volatility & Risk

The Cooper Companies has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Neogen has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.

Valuation and Earnings

This table compares The Cooper Companies and Neogen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Cooper Companies$2.43 billion7.88$238.40 million$9.6440.45
Neogen$418.17 million11.66$59.47 million$1.1380.62

The Cooper Companies has higher revenue and earnings than Neogen. The Cooper Companies is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.8% of The Cooper Companies shares are held by institutional investors. Comparatively, 92.8% of Neogen shares are held by institutional investors. 1.4% of The Cooper Companies shares are held by company insiders. Comparatively, 0.9% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for The Cooper Companies and Neogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Cooper Companies04702.64
Neogen02102.33

The Cooper Companies presently has a consensus target price of $385.50, suggesting a potential downside of 1.23%. Neogen has a consensus target price of $81.50, suggesting a potential downside of 10.54%. Given The Cooper Companies' stronger consensus rating and higher probable upside, analysts clearly believe The Cooper Companies is more favorable than Neogen.

Profitability

This table compares The Cooper Companies and Neogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Cooper Companies9.81%12.79%7.20%
Neogen13.92%8.13%7.45%

Summary

The Cooper Companies beats Neogen on 11 of the 14 factors compared between the two stocks.

Neogen (NASDAQ:NEOG) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

Neogen has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Earnings and Valuation

This table compares Neogen and DENTSPLY SIRONA's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neogen$418.17 million11.66$59.47 million$1.1380.62
DENTSPLY SIRONA$4.03 billion3.62$262.90 million$2.4527.28

DENTSPLY SIRONA has higher revenue and earnings than Neogen. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.8% of Neogen shares are held by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are held by institutional investors. 0.9% of Neogen shares are held by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Neogen and DENTSPLY SIRONA, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neogen02102.33
DENTSPLY SIRONA14602.45

Neogen presently has a consensus price target of $81.50, suggesting a potential downside of 10.54%. DENTSPLY SIRONA has a consensus price target of $60.00, suggesting a potential downside of 10.22%. Given DENTSPLY SIRONA's stronger consensus rating and higher probable upside, analysts plainly believe DENTSPLY SIRONA is more favorable than Neogen.

Profitability

This table compares Neogen and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neogen13.92%8.13%7.45%
DENTSPLY SIRONA-1.40%7.13%4.13%

Summary

DENTSPLY SIRONA beats Neogen on 8 of the 14 factors compared between the two stocks.

Neogen (NASDAQ:NEOG) and STAAR Surgical (NASDAQ:STAA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

Neogen has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Earnings and Valuation

This table compares Neogen and STAAR Surgical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neogen$418.17 million11.66$59.47 million$1.1380.62
STAAR Surgical$150.18 million33.70$14.05 million$0.46234.63

Neogen has higher revenue and earnings than STAAR Surgical. Neogen is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.8% of Neogen shares are held by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are held by institutional investors. 0.9% of Neogen shares are held by insiders. Comparatively, 3.9% of STAAR Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Neogen and STAAR Surgical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neogen02102.33
STAAR Surgical03302.50

Neogen presently has a consensus price target of $81.50, suggesting a potential downside of 10.54%. STAAR Surgical has a consensus price target of $78.40, suggesting a potential downside of 27.41%. Given Neogen's higher probable upside, equities research analysts plainly believe Neogen is more favorable than STAAR Surgical.

Profitability

This table compares Neogen and STAAR Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neogen13.92%8.13%7.45%
STAAR Surgical5.73%8.99%7.12%

Neogen (NASDAQ:NEOG) and Quidel (NASDAQ:QDEL) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

Neogen has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Profitability

This table compares Neogen and Quidel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neogen13.92%8.13%7.45%
Quidel36.91%63.31%40.55%

Earnings and Valuation

This table compares Neogen and Quidel's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neogen$418.17 million11.66$59.47 million$1.1380.62
Quidel$534.89 million9.23$72.92 million$2.7342.49

Quidel has higher revenue and earnings than Neogen. Quidel is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.8% of Neogen shares are held by institutional investors. Comparatively, 84.0% of Quidel shares are held by institutional investors. 0.9% of Neogen shares are held by insiders. Comparatively, 14.1% of Quidel shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Neogen and Quidel, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neogen02102.33
Quidel10302.50

Neogen presently has a consensus price target of $81.50, suggesting a potential downside of 10.54%. Quidel has a consensus price target of $182.75, suggesting a potential upside of 57.54%. Given Quidel's stronger consensus rating and higher probable upside, analysts plainly believe Quidel is more favorable than Neogen.

Summary

Quidel beats Neogen on 10 of the 14 factors compared between the two stocks.


Neogen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
2.1$556.23+1.4%$43.42 billion$2.41 billion25.31Insider Selling
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$329.13+1.3%$23.98 billion$1.84 billion86.84Insider Selling
The Cooper Companies logo
COO
The Cooper Companies
1.9$389.97+1.3%$18.91 billion$2.43 billion81.08
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$66.83+1.7%$14.34 billion$4.03 billion-290.57Earnings Announcement
Analyst Report
Analyst Revision
STAAR Surgical logo
STAA
STAAR Surgical
1.4$107.93+2.6%$5.20 billion$150.18 million568.08Analyst Report
Insider Selling
News Coverage
Quidel logo
QDEL
Quidel
2.4$116.00+3.4%$5.10 billion$534.89 million13.62Analyst Report
ICU Medical logo
ICUI
ICU Medical
1.7$193.40+1.3%$4.05 billion$1.27 billion51.16Earnings Announcement
Insider Selling
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.7$59.37+0.5%$3.31 billion$994.85 million-112.02Insider Selling
Haemonetics logo
HAE
Haemonetics
2.1$51.96+15.1%$3.04 billion$988.48 million25.10News Coverage
Gap Down
Atrion logo
ATRI
Atrion
1.1$596.61+3.4%$1.09 billion$155.07 million33.61
Cerus logo
CERS
Cerus
1.7$5.60+0.5%$953.43 million$74.65 million-14.36Analyst Revision
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$18.16+0.8%$780.37 million$253.67 million16.81Earnings Announcement
Analyst Report
Analyst Revision
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$9.25+0.3%$667.79 million$154.60 million-40.22Analyst Downgrade
Analyst Revision
Antares Pharma logo
ATRS
Antares Pharma
1.8$3.81+1.0%$636.37 million$123.86 million63.51Analyst Report
Analyst Revision
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$42.56+0.8%$607.30 million$114.51 million-90.55
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.34+2.0%$318.44 million$46.90 million27.55Dividend Announcement
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.